Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Current Scenario and Future Prospects of Adverse Drug Reactions (ADRs) Monitoring and Reporting Mechanisms in the Rural Areas of India

Author(s): Shalini Shukla, Priyanka Sharma, Priya Gupta, Shikha Pandey, Reshu Agrawal, Deepak Rathour, Dharmendra Kumar Kewat, Ramu Singh, Sunil Kumar Thakur, Rishi Paliwal and Kunjbihari Sulakhiya*

Volume 19, Issue 2, 2024

Published on: 15 May, 2023

Page: [172 - 190] Pages: 19

DOI: 10.2174/1574886318666230428144120

Price: $65

Abstract

Background: Pharmacovigilance (PV) deals with the detection, collection, assessment, understanding, and prevention of adverse effects associated with drugs. The objective of PV is to ensure the safety of the medicines and patients by monitoring and reporting all adverse drug reactions (ADRs) associated with prescribed medicine usage. Findings have indicated that about 0.2- 24% of hospitalization cases are due to ADRs, of which 3.7% of patients have lethal ADRs. The reasons include the number of prescribed drugs, an increased number of new medicines in the market, an inadequate PV system for ADR monitoring, and a need for more awareness and knowledge about ADR reporting. Severe ADRs lead to enhanced hospital stays, increased treatment costs, risk of death, and many medical and economic consequences. Therefore, ADR reporting at its first instance is essential to avoid further harmful effects of the prescribed drugs. In India, the rate of ADR reporting is less than 1%, whereas worldwide, it is 5% due to a need for more awareness about PV and ADR monitoring among healthcare providers and patients. The main objective of this review is to highlight the current scenario and possible futuristic ways of ADR reporting methods in rural areas of India. We have searched the literature using PubMed, Google scholar, Indian citation index to retrieve the resources related to ADR monitoring and reporting in India's urban and rural areas. Spontaneous reporting is the most commonly used PV method to report ADRs in India's urban and rural areas. Evidence revealed that no effective ADR reporting mechanisms developed in rural areas causing underreporting of ADR, thus increasing the threat to the rural population. Hence, PV and ADR reporting awareness among healthcare professionals and patients, telecommunication, telemedicine, use of social media and electronic medical records, and artificial intelligence are the potential approaches for prevention, monitoring, and reporting of ADRs in rural areas.

« Previous Next »
Graphical Abstract

[1]
WHO 2020. Available from: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/
[2]
Munjal S. An introduction to pharmacovigilance: What a cardiologist must know. J Clin Prev Cardiol 2016; 5(4): 143.
[http://dx.doi.org/10.4103/2250-3528.192698]
[3]
Safety of medicines: A guide to detecting and reporting adverse drug reactions: Why health professionals need to take action; World Health Organization 2002. Available from: https://apps.who.int/iris/handle/10665/67378
[4]
Choudhary AK, Nivedhitha S, Radhakrishna L, Tirumalaikolundusubrimnian P, Manicvasagam S. Perception of adverse drug reaction among doctors, nurses and pharmacists of a tertiary care rural teaching hospital. Internet J Pharmacol 2013; 12(1): 143.
[5]
Chandrakapure A, Giri S, Khan I, Mateenuddin M, Faheem M. Pharmacovigilance: A study to evaluate knowledge, attitude, and practices of and impact of educational intervention among doctors in teaching hospital, in rural area of Jalna, India. Int J Basic Clin Pharmacol 2015; 4: 427-31.
[http://dx.doi.org/10.18203/2319-2003.ijbcp20150008]
[6]
Biswas P, Biswas A. Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol 2007; 39(3): 124.
[http://dx.doi.org/10.4103/0253-7613.33431]
[7]
The importance of pharmacovigilance. 2002. Available from: https://apps.who.int/iris/handle/10665/42493
[8]
The Pharma Letter. India needs to address major problems of adverse drug reactions. 2020. Available from: https://www.thepharmaletter.com/article/india-needs-to-address-major-problems-of-adverse-drug-reactions
[9]
Kumar A. Past, present and future of pharmacovigilance in India. Sys Rev Pharm 2011; 2(1): 55.
[http://dx.doi.org/10.4103/0975-8453.83440]
[10]
Dhikav V, Singh S, Anand KS. Adverse drug reaction monitoring in India. J Indian Acad Clin Med 2004; 5(1): 27-33.
[11]
Thomas KB. Chloroform: Commissions and omissions. Proc R Soc Med 1974; 67(8): 723-30.
[http://dx.doi.org/10.1177/003591577406700816]
[12]
Ballentine C. Sulfanilamide disaster FDA Consumer magazine. 1981. Available from: https://www.fda.gov/about-fda/histories-product-regulation/sulfanilamide-disaster
[13]
West JG. The accidental poison that founded the modern FDA. 2020. Available from: https://www.theatlantic.com/technology/archive/2018/01/the-accidental-poison-that-founded-the-modern-fda/550574/
[14]
Suke SG, Kosta P, Negi H. Role of pharmacovigilance in India: An overview. Online J Public Health Inform 2015; 7(2): e223.
[http://dx.doi.org/10.5210/ojphi.v7i2.5595] [PMID: 26392851]
[15]
Vargesson N. Thalidomide‐induced teratogenesis: History and mechanisms. Birth Defects Res C Embryo Today 2015; 105(2): 140-56.
[http://dx.doi.org/10.1002/bdrc.21096] [PMID: 26043938]
[16]
Drug makers warned for potential diethylene glycol toxin contamination. 2020. Available from: https://www.drugwatch.com/news/2020/04/20/diethylene-glycol-toxin-contamination/
[17]
Mansel-Jones D. The role of the committee on safety of drugs. Br Med Bull 1970; 26(3): 257-9.
[http://dx.doi.org/10.1093/oxfordjournals.bmb.a070794] [PMID: 4922462]
[18]
Ashwlayan VD, Nimesh S. Pharmacovigilance: An Overview. Int J Pharm 2018; 3(1): 1-6.
[http://dx.doi.org/10.15226/2476-2431/3/1/00124]
[19]
W.H.O. 2020.Available From https://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/
[20]
Vakil BJ, Kulkarni RD, Chabria NL, Chadha DR, Deshpande VA. Intense surveillance of adverse drug reactions. An analysis of 338 patients. J Clin Pharmacol 1975; 15(5-6): 435-41.
[http://dx.doi.org/10.1002/j.1552-4604.1975.tb02365.x] [PMID: 1133220]
[21]
Thatte UM, Chaudhari NL, Gogtay NJ. Pharmacovigilance program of India: History, evolution and current status. Adverse Drug React Bull 2018; 312(1): 1207-10.
[http://dx.doi.org/10.1097/FAD.0000000000000036]
[22]
Lihite RJ, Lahkar M. An update on the pharmacovigilance programme of India. Front Pharmacol 2015; 6: 194.
[http://dx.doi.org/10.3389/fphar.2015.00194] [PMID: 26441651]
[23]
Coleman JJ. Adverse drug reactions. Clin Med 2016; 16(5): 481-5.
[24]
Dikshit RK, Desai C, Desai MK. Pleasures and pains of running a pharmacovigilance center. Indian J Pharmacol 2008; 40 (Suppl. 1): S31-4.
[PMID: 21369412]
[25]
Kengar MD, Patole KK, Ade AK, Kumbhar SM, Patil CD, Ganjave AR. Introduction to pharmacovigilance and monitoring. Asian J Pharm Res 2019; 9(2): 116-22.
[http://dx.doi.org/10.5958/2231-5691.2019.00019.4]
[26]
Society of pharmacovigilance, India. Wikipedia, The free encyclopedia. 2016. Available from: https://en.wikipedia.org/w/index.php?title=Society_of_Pharmacovigilance,_India&oldid=755648023/
[27]
Amale PN, Sa D, Yd N, Na A. Pharmacovigilance process in India: An overview. J Pharmacovigil 2018; 6(2): 259.
[http://dx.doi.org/10.4172/2329-6887.1000259]
[28]
Amale PN, Sa D, Yd N, Na A. Pharmacovigilance programme of India: The journey travelled and the way forward. WHO Drug Information 2018; 32(1): 10-7.
[29]
Vivekanandan K, Prakash J, Singh G. Pharmacovigilance programme of India. Arch Pharm Pract 2012; 3(3): 229-32.
[http://dx.doi.org/10.4103/2045-080X.116605]
[30]
Guidance document for reporting serious adverse reactions in blood transfusion service. 2012. Available from: www.ipc.gov.in/
[31]
Kalaiselvan V, Thota P, Singh G. Pharmacovigilance programme of India: Recent developments and future perspectives. Indian J Pharmacol 2016; 48(6): 624-8.
[http://dx.doi.org/10.4103/0253-7613.194855] [PMID: 28066097]
[32]
Meher BR. Materiovigilance: An Indian perspective. Perspect Clin Res 2018; 9(4): 175-8.
[PMID: 30319948]
[33]
Thota P, Agrawal V, Shrivastava TP, Adusumilli PK, Vivekanandan K, Bhushan S. Pivotal role of pharmacovigilance programme of India in containment of antimicrobial resistance in India. Perspect Clin Res 2019; 10(3): 140-4.
[http://dx.doi.org/10.4103/picr.PICR_29_18] [PMID: 31404182]
[34]
WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services in India launched. 2020. Available from: http://www. searo.who.int/india/mediacentre/events/2017/CC_pharmacovigilance/en/
[35]
Kalaiserian V, Thota P, Singh A. Current status of adverse drug reactions monitoring centres under pharmacovigilance programme of India. Ind JPharmacy Practice 2014; 7(3): 19-22.
[http://dx.doi.org/10.5530/ijopp.7.3.5]
[36]
Available from: http://www.pharmabiz.com/ArticleDetails.aspx?aid=115023&sid=1/
[37]
The role of technology in evolving pharmaceutical secto 2021. Available from: http://pharmabiz.com/ArticleDetails.aspx?aid=117664&sid=1/
[38]
Available from: http://www.ipc.gov.in/images/SDP_2020_Calendar.pdf/
[39]
Mulchandani R, Kakkar AK. Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions. Int J Risk Saf Med 2018; 30(1): 33-44.
[http://dx.doi.org/10.3233/JRS-180025] [PMID: 30175985]
[40]
Kavya HB. Recent development of pharmacovigilance system in India. J Pharma Care Health Sys 2018; 5: 193.
[41]
Swain T, Nityadarshini N, Pattnaik S, Swain K. Knowledge, attitude and practice study regarding pharmacovigilance programme of India among private practitioners in urban Odisha, India. Int J Basic Clin Pharmacol 2016; 5(4): 1315-20.
[http://dx.doi.org/10.18203/2319-2003.ijbcp20162428]
[42]
Pimpalkhute S, Jaiswal KM, Bajait CS, Gaikwad A, Sontakke SD. Evaluation of awareness about pharmacovigilance and adverse drug reaction monitoring in resident doctors of a tertiary care teaching hospital. Indian J Med Sci 2012; 66(3): 55-61.
[http://dx.doi.org/10.4103/0019-5359.110902] [PMID: 23603621]
[43]
Vora MB, Nagar JG, Patel PB, Upadhyaya HB. Knowledge, attitude and practices toward pharmacovigilance and adverse drug reactions in postgraduate students of Tertiary Care Hospital in Gujarat. J Adv Pharm Technol Res 2015; 6(1): 29-34.
[http://dx.doi.org/10.4103/2231-4040.150369] [PMID: 25709967]
[44]
Sevene E, Mariano A, Mehta U, et al. Spontaneous adverse drug reaction reporting in rural districts of Mozambique. Drug Saf 2008; 31(10): 867-76.
[http://dx.doi.org/10.2165/00002018-200831100-00005] [PMID: 18759510]
[45]
Jacobs TG, Hilda Ampadu H, Hoekman J, Dodoo ANO, Mantel-Teeuwisse AK. The contribution of Ghanaian patients to the reporting of adverse drug reactions: A quantitative and qualitative study. BMC Public Health 2018; 18(1): 1384.
[http://dx.doi.org/10.1186/s12889-018-6285-9] [PMID: 30563498]
[46]
Datta S, Sengupta S. An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting in a tertiary care teaching hospital of Sikkim. Perspect Clin Res 2015; 6(4): 200-6.
[http://dx.doi.org/10.4103/2229-3485.167096] [PMID: 26623391]
[47]
Joshi A, Shah N, Mistry M, Gor A. Evaluation of knowledge and perception toward adverse drug reactions among patients visiting tertiary-care teaching hospital. Natl J Physiol Pharm Pharmacol 2015; 5(4): 280.
[http://dx.doi.org/10.5455/njppp.2015.5.2502201543]
[48]
Schade CP, Ruddick P, Lomely DR, Bellamy G. Voluntary adverse event reporting in rural hospitals Advances in patient safety: New directions and alternative approaches. Rockville: Agency for Healthcare Research and Quality 2008; p. 1.
[49]
Limaye Dnyanesh GF, Limaye V, Chaudhari J, Desai R, Dikshit A, Lalge R. Implementing a pharmacovigilance program in Rural India. SOCRA Source 2016; 2016: 30.
[50]
Tandon V, Mahajan V, Khajuria V, Gillani Z. Under-reporting of adverse drug reactions: A challenge for pharmacovigilance in India. Indian J Pharmacol 2015; 47(1): 65-71.
[http://dx.doi.org/10.4103/0253-7613.150344] [PMID: 25821314]
[51]
Gupta PJ. The role of quacks in the practice of proctology. Eur Rev Med Pharmacol Sci 2010; 14(9): 795-8.
[PMID: 21061840]
[52]
Nandal DH, Mahajan SN, Narwane SP, Kunkulol RR, Baheti T. (Adverse Drug Reactions) Reporting in Pravara Rural Hospital, Loni. Pravara Med Rev 2019; 11(1): 4-7.
[53]
Deepalakshmi M, Kumar P, Arun KP, Ponnusankar S. Impact of continuing pharmacy education on the knowledge, attitude and practice of community pharmacists about ADR monitoring and reporting. Indian J Pharm Sci 2019; 81(4): 633-9.
[54]
Agrawal M, Singh P, Hishikar R, Joshi U, Maheshwari B, Halwai A. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year. Indian J Pharmacol 2017; 49(6): 432-7.
[http://dx.doi.org/10.4103/ijp.IJP_781_16] [PMID: 29674797]
[55]
Venkatasubbaiah M, Dwarakanadha Reddy P, Satyanarayana SV. Analysis and reporting of adverse drug reactions at a tertiary care teaching hospital. Alex J Med 2018; 54(4): 597-603.
[http://dx.doi.org/10.1016/j.ajme.2018.10.005]
[56]
Richa, Tandon VR, Sharma S, Khajuria V, Mahajan V, Gillani Z. Adverse drug reactions profile of antimicrobials: A 3-year experience, from a tertiary care teaching hospital of India. Indian J Med Microbiol 2015; 33(3): 393-400.
[http://dx.doi.org/10.4103/0255-0857.158564] [PMID: 26068342]
[57]
Gupta S, Nayak R, Shivaranjani R, Vidyarthi S. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. Perspect Clin Res 2015; 6(1): 45-52.
[http://dx.doi.org/10.4103/2229-3485.148816] [PMID: 25657902]
[58]
Wahlang JB, Laishram PD, Brahma DK, Sarkar C, Lahon J, Nongkynrih BS. Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Ther Adv Drug Saf 2017; 8(2): 61-6.
[http://dx.doi.org/10.1177/2042098616672572] [PMID: 28255433]
[59]
Singh A, Dwivedi S. Study of adverse drug reactions in patients with diabetes attending a tertiary care hospital in New Delhi, India. Indian J Med Res 2017; 145(2): 247-9.
[PMID: 28639602]
[60]
Siddiqui AN, Khayyam KU, Sharma M. Effect of diabetes mellitus on tuberculosis treatment outcome and adverse reactions in patients receiving directly observed treatment strategy in India: A prospective study. BioMed Res Int 2016; 2016: 1-11.
[http://dx.doi.org/10.1155/2016/7273935] [PMID: 27642601]
[61]
Sadiq S, Khajuria V, Tandon VR, Mahajan A, Singh JB. Adverse drug reaction profile in patients on anti-tubercular treatment alone and in combination with highly active antiretroviral therapy. J Clin Diagn Res 2015; 9(10): FC01-4.
[http://dx.doi.org/10.7860/JCDR/2015/13452.6652] [PMID: 26557538]
[62]
Nandy M, Naser SM, Banu P, et al. Adverse drug reaction monitoring through active surveillance of antitubercular therapy in an urban tertiary care center. Comm Acq Inf 2016; 3(2): 51.
[http://dx.doi.org/10.4103/2225-6482.184913]
[63]
Medhi B, Saini VK, Sewal RK, Ahmad Y. Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian J Pharm Sci 2015; 77(6): 687-93.
[http://dx.doi.org/10.4103/0250-474X.174990] [PMID: 26997696]
[64]
Mangla R, Verma S, Gupta MC, Singhal S. Adverse drug reaction monitoring of commonly prescribed medicines in gynecology patients in a tertiary care hospital in North India. Int J Health Sci Res 2017; 7: 111-7.
[65]
Nair SA. 19-Year retrospective study of adverse drug reactions to multidrug therapy in leprosy requiring a change in regime. Indian Dermatol Online J 2018; 9(1): 33-6.
[http://dx.doi.org/10.4103/idoj.IDOJ_116_17] [PMID: 29441295]
[66]
Prathyusha K, Rao AY, Praneeth G, Kishore P. Pattern of adverse drug reactions in cancer patients at a tertiary care hospital in Telangana Region of South India. Asian J Pharm Clin Res 2018; 6(4)
[67]
Nimesh S, Tomar R, Kumar M, Tyagi N, Shukla PK. A pharmacovigilance study of monitoring & focusing of adverse drug reactions induced by antiepileptic drugs used in epileptic patients. Pharm Pharmacol Int J 2019; 7(3): 100-4.
[http://dx.doi.org/10.15406/ppij.2019.07.00238]
[68]
Das B, Ramasubbu SK, Pasricha RK, Nath UK. Frequency, nature, severity and preventability of adverse drug reactions arising from cancer chemotherapy in a teaching hospital. J Family Med Prim Care 2020; 9(7): 3349-55.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_352_20] [PMID: 33102295]
[69]
Aggarwal M, Chawla S, Singh K, Rana P. Evaluation of anticancer drug utilization and monitoring of adverse drug reaction in the indoor patients receiving cancer chemotherapy in a Tertiary Care Hospital in New Delhi. J Basic Clin Physiol Pharmacol 2018; 9(2): 118-22.
[70]
Damodar SK, Joseph J, Cheaten S, Rajendran N, Vijayan PM, Guru G. Assessment of knowledge, awareness and practices among healthcare professionals about pharmacovigilance and adverse drug reactions reporting in Dharmapuri and Krishnagiri Districts of Tamilnadu, India. J Pharm Practice Comm Med 2018; 4(1): 33-8.
[http://dx.doi.org/10.5530/jppcm.2018.1.9]
[71]
Dimri D, Raina RS, Thapliyal S, Thawani V. Retrospective analysis of pattern of cutaneous adverse drug reactions in Tertiary Hospital of Pauri Garhwal. J Clin Diagn Res 2016; 10(5): FC01-6.
[http://dx.doi.org/10.7860/JCDR/2016/16938.7736] [PMID: 27437240]
[72]
Kharb P, Mittal N, Gupta M. An evaluation of adverse drug reactions monitoring at a pharmacovigilance unit under pharmacovigilance program of India in a tertiary care hospital of Haryana. Int J Basic Clin Pharmacol 2015; 4(3): 556-60.
[http://dx.doi.org/10.18203/2319-2003.ijbcp20150039]
[73]
Tarun Teja PB, Ramraj B. Study of proportion and pattern of adverse drug events among patients coming to health centers in urban and rural areas. Int J Community Med Public Health 2018; 5(8): 3423-8.
[http://dx.doi.org/10.18203/2394-6040.ijcmph20183074]
[74]
Digra KK, Pandita A, Saini GS, Bharti R. Pattern of adverse drug reactions in children attending the department of pediatrics in a tertiary care center: A prospective observational studyClin Med Insights Pediatr 2015; 9: 73-8.
[http://dx.doi.org/ 10.4137/CMPed.S29493] [PMID: 26309424]
[75]
Gor AP, Desai SV. Adverse drug reactions (ADR) in the inpatients of medicine department of a rural tertiary care teaching hospital and influence of pharmacovigilance in reporting ADR. Indian J Pharmacol 2008; 40(1): 37-40.
[http://dx.doi.org/10.4103/0253-7613.40488] [PMID: 21264160]
[76]
Gangadhar M, Guruppanavar D. Assessment of knowledge, attitude and perception of Pharmacovigilance among nurses in a rural tertiary care center. Int J Basic Clin Pharmacol 2015; 4(5): 1009-12.
[http://dx.doi.org/10.18203/2319-2003.ijbcp20150883]
[77]
Krishna J, Babu GC, Goel S, et al. A prospective study of incidence and assessment of Adverse Cutaneous Drug Reactions as a part of Pharmacovigilance from a rural northern Indian medical school. Int Arch Integr Med 2015; 2(6): 108-15.
[78]
Patil SB, Raikar SR. H N B, Janardhan M, Rao YV, Vahifa. A study of adverse drug reactions in patients treated with Penicillins in a Rural Tertiary Care Hospital. Int J Pharmacol Clinic Sci 2016; 5(2): 41-4.
[http://dx.doi.org/10.5530/ijpcs.5.2.1]
[79]
Deshmukh VS, Motghare VM, Gajbhiye D, Sv B, Deshpande R, Pise H. Study on acute adverse drug reactions of antisnake venom in a rural tertiary care hospital. Asian J Pharm Clin Res 2014; 7(5): 13-5.
[80]
Patil S, Raikar S, Janardhan M, Rao YNB, Vahila N. A profile of adverse drug reactions in a rural tertiary care hospital. Natl J Physiol Pharm Pharmacol 2016; 6(6): 559-62.
[http://dx.doi.org/10.5455/njppp.2016.6.0514317062016]
[81]
The pharmacovigilance market dynamic 2017. 2020. Available from: http://www.pharmafile.com/news/520381/pv-futures-pharmacovigilance-solution-challenges-tomorrow/accssesd
[82]
Sawarkar A, Sharma RK, Gautam V, Shramankar K, Dinodia N. Pharmacovigilance: Present status and future perspectives. Pharma Innov 2019; 8(8): 84-92.
[83]
Pahuja R, Shrivastava B, Sharma PK, Kishore K, Mahajan S, Sood R. Awareness on adverse drug reaction reporting system in India: A consumer survey. American J Phytomed Clin Thera 2014; 2(12): 1361-9.
[84]
Jamshed N, Ozair FF, Sharma A, Aggarwal P. Ethical issues in electronic health records: A general overview. Perspect Clin Res 2015; 6(2): 73-6.
[http://dx.doi.org/10.4103/2229-3485.153997] [PMID: 25878950]
[85]
Liu M, McPeek Hinz ER, Matheny ME, et al. Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records. J Am Med Inform Assoc 2013; 20(3): 420-6.
[http://dx.doi.org/10.1136/amiajnl-2012-001119] [PMID: 23161894]
[86]
National digital health mission 2020. Available from: https://www.drishtiias.com/daily-updates/daily-news-analysis/national-digital-health-mission/
[87]
Explained: What is National Digital Health Mission and how it will benefit people 2020. Available from: https://www.hindustantimes.com/india-news/explained-what-is-national-digital-health-mission-and-how-it-will-benefit-people/story-qOKlv3rbkrvB0aR9ZQyvdK.html/
[88]
Pappa D, Stergioulas LK. Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions. Int J Data Sci Anal 2019; 8(2): 113-35.
[http://dx.doi.org/10.1007/s41060-019-00175-3]
[89]
Cobert B, Biron P. Practical drug safety from A to Z . Jones & Bartlett Publishers Massachusetts 2009.
[90]
How is Artificial Intelligence shaping the healthcare and pharma industry? 2020. Available from: https://ehealth.eletsonline.com/2020/01/how-is-artificial-intelligence-shaping-the-healthcare-and-pharma-industry/

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy